en · de · es · pt
tb-500-notes.peptides6088.com › Wiki › Tb-500 Identity And Chemical Background — Worked Examples

Tb-500 Identity And Chemical Background — Worked Examples

By Editorial Desk · published 2025-07-28 · last reviewed 2025-08-30 · Wiki

Ac-SDKP raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

This page was last updated on 2025-08-30 and is reviewed periodically as new material appears.

TB-500 Identity and Chemical Background

Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.

Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.

TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.

TB-500 Background and Identity

Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.

TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.

The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.

Tb-500 at a glance

PropertyValueNotes
Physical formLyophilised powderSealed vial; reconstituted before laboratory use
AppearanceWhite to off-white solidVisual descriptor used on certificates of analysis
Solubility classWater-solubleDissolves in water and aqueous buffers
Reported mass, fragmentNear 889 DaValue depends on the stated sequence
Reported mass, parent proteinNear 4963 Da43-residue thymosin beta-4

Storage and Analytical Verification

Dry powder is commonly held at minus twenty degrees Celsius, with some suppliers recommending lower temperatures for long-term archival storage. Once dissolved, solutions are typically kept cold and protected from light, since aqueous peptide solutions can lose integrity through hydrolysis or oxidation over time. Stability data specific to this fragment are limited in the public literature, and much of the guidance comes from general peptide handling practice rather than from controlled degradation studies. Users therefore treat stated shelf lives as approximate rather than fixed.

Identity and purity are normally assessed with reversed-phase high-performance liquid chromatography, paired with mass spectrometry to confirm molecular mass. A certificate of analysis reports a purity percentage, usually derived from chromatographic peak area, but that figure does not by itself prove a correct sequence or the absence of counterions. Independent verification may include amino acid analysis or peptide mapping. Batch-to-batch variation is a documented concern in the research chemical market, and the gap between a quoted purity value and actual peptide content can be substantial when the material is a salt or retains residual water.

Related pages on this site

Identity And Naming Background

TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.

Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.

TB-500 Identity and Molecular Background

Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.

Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.

TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.

Further detail

== Description == Parkia biglobosa is a dicotyledonous angiosperm belonging to the family Fabaceae (Caesalpinioideae - Mimosoid clade). It is a deciduous perennial that grows to between 7 and 20 metres high, in some cases up to 30 metres. The tree is a fire-resistant heliophyte characterized by a thick dark gray-brown bark. The pods of the tree, commonly referred to as locust beans, are pink in the beginning and turn dark brown when fully mature. They are 30-40 centimetres long on average, with some reaching lengths of about 45 centimetres. Each pod can contain up to 30 seeds; the seeds are embedded in a sweet, powdery yellow pulp.

=== Politics === Liberal Democracy of Slovenia, a political party in Slovenia Liberal Democratic Party (Serbia, 1989), a defunct political party in Serbia Linyon Demokratik Seselwa, a political party in Seychelles

In animals, the main excretory products are carbon dioxide, ammonia (in ammoniotelics), urea (in ureotelics), uric acid (in uricotelics), guanine (in Arachnida), and creatine. The liver and kidneys clear many substances from the blood (for example, in renal excretion), and the cleared substances are then excreted from the body in the urine and feces. Aquatic animals usually excrete ammonia directly into the external environment, as this compound has high solubility and there is ample water available for dilution. In terrestrial animals, ammonia-like compounds are converted into other nitrogenous materials, i.e. urea, that are less harmful as there is less water in the environment and ammonia itself is toxic. This process is called detoxification.

In June 2024, Adam Hamawy, a former US army combat surgeon who worked in the European Hospital, stated, "But the level of civilian casualties that I experienced was beyond anything I'd seen before... Most of our patients were children under the age of 14". In August 2024, an Israeli airstrike killed Joumana Arafa and her four-day-old twins.

Chorea-acanthocytosis (ChAc, also called choreoacanthocytosis) is a rare hereditary disease—evidence suggests that only 500 to 1,000 people worldwide have the condition. It is caused by a mutation in a gene that directs structural proteins in red blood cells. It belongs to a group of four diseases characterized under the name neuroacanthocytosis. When a patient's blood is viewed under a microscope, some of the red blood cells appear thorny. These thorny cells are called acanthocytes. Other effects of the disease may include involuntary muscle movements, impaired balance and coordination, behavioral changes, memory problems, difficulty swallowing, speech difficulties, seizures, muscle weakness, personality changes, and neuronal degradation similar to Huntington's disease. The average age of onset of symptoms is 35 years. The disease is incurable and inevitably leads to premature death. Chorea-acanthocytosis is a very complex autosomal recessive adult-onset neurodegenerative disorder. It often shows itself as a mixed movement disorder, in which chorea, tics, dystonia and even parkinsonism may appear as a symptom. This disease is also characterized by the presence of a few different movement disorders including chorea, dystonia etc. Chorea-acanthocytosis is considered an autosomal recessive disorder, although a few cases with autosomal dominant inheritance have been noted.

Sources: en.wikipedia.org

Supporting material

Food and Drug Administration (FDA) on 24 July 2015, and evolocumab (Repatha, Amgen), approved on 27 August 2015; both were also authorised in the European Union in 2015. Inclisiran (Leqvio, Novartis), a small interfering RNA (siRNA) that reduces PCSK9 production in the liver and is administered by twice-yearly injection, was subsequently approved by the European Medicines Agency in December 2020 and by the FDA in December 2021. PCSK9 inhibitors have been shown to significantly reduce LDL-C levels and increase HDL-C levels significantly. They were found to lower the incidence of myocardial infarction and stroke in individuals at high cardiovascular risk (over 15% using PREDICT cardiovascular disease calculator), such as those with at least five risk factors, established cardiovascular disease, or hereditary lipid disorders without cardiovascular risk factor, but not in those at low to moderate risk. A 2023 meta-analysis has indicated that alirocumab may reduce all-cause mortality, whereas evolocumab has no significant effect on all-cause mortality. The efficacy of bococizumab remains unclear, as its development was discontinued by Pfizer in 2016. The most recent guidelines for cholesterol management from the American Heart Association and American College of Cardiology now provide guidance for when PCSK9 inhibitors should be considered, particularly focusing on cases in which maximally tolerated statin and ezetimibe fail to achieve goal LDL reduction. A possible side effect of the monoclonal antibody might be irritation at the injection site.

The fifth season had twelve roles receiving star billing, with eleven of them returning from the previous season, eight of which part of the original cast from the first season, and three new cast members being added. Kerry Washington continued to play her role as protagonist of the series, Olivia Pope, a former White House Director of Communications with her own crisis management firm. Darby Stanchfield played Abby Whelan, the White House Press Secretary, Katie Lowes portrayed Quinn Perkins, and Guillermo Diaz portrayed Huck, the troubled tech guy who works for Olivia. Cornelius Smith Jr. continued his role as activist Marcus Walker. after being upgraded to series regular. Jeff Perry continued to portray Cyrus Beene, chief of staff at the White House who was fired by Fitz but later rehired. Portia de Rossi played Elizabeth North, the new chief of staff at the White House, and later the chief of staff for the vice president. Joshua Malina played the role of David Rosen, former U.S. Attorney, now Attorney General. Bellamy Young continued to act as First Lady/Senator Melody "Mellie" Grant, who was kicked out of the White House by Fitz, and later joined the presidential campaign for president. Tony Goldwyn continued to portray President Fitzgerald "Fitz" Thomas Grant III. Scott Foley portrayed Jake Ballard a former B613 agent and later the head of the NSA. On May 14, 2015, after the fourth-season finale, it was announced that Portia de Rossi had been promoted to a series regular for the fifth season.

== Significance == The transmembrane region of many integral membrane proteins consists of one or more alpha helices. The orientations and interactions of these helices directly affect cell signaling and molecular transport across the bilayer. The hydrophobic environment of the phospholipid tails in turn modulates the position and structure of such domains and thus may influence protein function. Conversely, the bilayer itself can (locally) change the thickness of its hydrocarbon region to interact optimally with hydrophobic regions of a transmembrane protein (a.k.a. hydrophobic matching). WALPs provide an effective model for studying such interactions because of their systematic design of a core of hydrophobic, alternating alanine and leucine regions. This core is readily manipulated by extending or decreasing the number of amino acids. Another key feature is the presence of "anchoring" residues at the ends of the helix, which are tryptophan residues in the WALP versions. Substituting the anchoring tryptophan residues for charged residues, such as lysine, yields "KALP" peptides. This class of model peptides has proved useful for studying the impact of changes in lipid composition on peptide insertion. Following detailed experimental studies by various techniques, the WALP and related peptides have become commonly used model systems in computational biology.

==== Systemic sickness ==== Since the 1990s, reviews of studies for causal relations between silicone-gel prosthetic breasts and systemic disease reported no causal relation to the occurrences of either systemic or autoimmune diseases; nonetheless, many women reported suffering neurological and rheumatological illnesses caused by failures of their prosthetic breasts. The study Long-term Health Status of Danish Women with Silicone Breast Implants (2004), reported that in relation to women of the general population, women with prosthetic breasts did not have a greater rate of incidence and diagnosis of autoimmune disease; that their rate of incidence for musculoskeletal disease was lower than the rate of incidence among women who had undergone other types of cosmetic surgery.

Sources: en.wikipedia.org

Notes from published material

D-Amino acids are amino acids where the stereogenic carbon alpha to the amino group has the D-configuration. For most naturally occurring amino acids, this carbon has the L-configuration. D-Amino acids are occasionally found in nature as residues in proteins. They are formed from ribosomally derived D-amino acid residues. Amino acids, as components of peptides, peptide hormones, structural and immune proteins, are the most important bioregulators involved in all life processes along with nucleic acids, carbohydrates and lipids. "Environmental ᴅ-amino acids are thought to be derived from organic diagenesis such as racemization and release from bacterial cell walls and even from microbial production."

=== Actual consequences === In retrospect, it is now known that smoke from the Kuwait oil fires only affected the weather pattern throughout the Persian Gulf and surrounding region during the periods that the fires were burning in 1991, with lower atmospheric winds blowing the smoke along the eastern half of the Arabian Peninsula, and cities such as Dhahran and Riyadh, and countries such as Bahrain experienced days with smoke filled skies and carbon soot rainout/fallout. Thus the immediate consequence of the arson sabotage was a dramatic regional decrease in air quality, causing respiratory problems for many Kuwaitis and those in neighboring countries. According to the 1992 study from Peter Hobbs and Lawrence Radke, daily emissions of sulfur dioxide (which can generate acid rain) from the Kuwaiti oil fires were 57% of that from electric utilities in the United States, the emissions of carbon dioxide were 2% of global emissions and emissions of soot reached 3400 metric tons per day. In a paper in the DTIC archive, published in 2000, it states that "Calculations based on smoke from Kuwaiti oil fires in May and June 1991 indicate that combustion efficiency was about 96% in producing carbon dioxide. While, with respect to the incomplete combustion fraction, Smoke particulate matter accounted for 2% of the fuel burned, of which 0.4% was soot." (With the remaining 2% being oil that did not undergo any initial combustion).

These kinases consist of extracellular domains, a transmembrane spanning alpha helix, and an intracellular tyrosine kinase domain protruding into the cytoplasm. They play important roles in regulating cell division, cellular differentiation, and morphogenesis. More than 50 receptor tyrosine kinases are known in mammals.

Sources: en.wikipedia.org

Frequently asked questions

Is TB-500 the same as thymosin beta-4?

No. TB-500 is a trade-style label used for a synthetic peptide described as a fragment of thymosin beta-4, while thymosin beta-4 is the full 43-residue protein. The two differ in size and are not interchangeable terms in analytical work.

Why do product listings show different sequences?

Naming for research peptides is not standardised, and suppliers sometimes apply the same label to different chain lengths. Certificates of analysis and mass data are the practical way to determine what a given lot contains.

What is the reported molecular mass?

The fragment commonly cited under this label is reported near 889 Da, and the parent protein near 4963 Da. Reported values shift with the exact sequence and with residual counter-ions or water in the sample.

What is TB-500?

TB-500 is a trade-style label for a synthetic peptide connected to thymosin beta-4. It is sold mainly through research-chemical channels and is not a single chemically defined product across suppliers.

Network